Cholera Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Cholera Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The cholera vaccines market is poised to grow at a CAGR of 9.8% over the forecast period.

The COVID-19 pandemic impacted the growth of the cholera vaccine market. For instance, an article published by the International Journal of Public Health in June 2021, reported cholera case fatality rate (CFR) increased in 2020 in Central and West Africa. CFR rose from 1.8% in 2019 to 2.1% in 2020. The COVID-19 pandemic has decreased health promotion activities that mitigate cholera outbreaks, and thus cases of cholera cases significantly increased. Thus, the increasing number of cholera cases reported during the COVID-19 pandemic increased the demand for cholera vaccines. In the current scenario, due to the decrease in COVID-19 cases and the resumption of healthcare services, the treatment of cholera is easily available, and the demand for the cholera vaccine may get stabilized compared to the beginning of the pandemic. In addition, with the rising number of cholera cases, the market is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are increasing incidences of cholera and rising initiatives and awareness regarding immunization. For instance, in December 2022 World Health Organization (WHO) reported that since 2021, there had been an increase in cholera cases and their geographical distribution globally. The source also repeated that in the year 2021, 23 countries reported cholera outbreaks, mainly in the WHO Regions of Africa and the Eastern Mediterranean.

Similarly, an article published by the journal The Lancet Regional Health South Asia in July 2022 reported 6,231 suspected cholera cases were recorded in Pakistan and Bangladesh from January 2022 to April 2022. Thus, the high number of cholera cases recorded globally is expected to increase the demand for cholera vaccines, thereby driving the growth of the studied market.

Also, the increasing research and developments in Asia are expected to drive the growth of the market. For instance, in October 2021, CSIR- Indian Institute of Chemical Biology developed an oral cholera vaccine with an avirulent culture of an El Tor vibrio strain isolated from a water source in India and had successful testing on human volunteers. Thus, such studies are leading to the development of new vaccines, thereby driving the growth of the studied market.

Furthermore, the increased funding for the development of cholera vaccines by various organizations is expected to drive the growth of the market. For instance, in January 2022, The International Vaccine Institute (IVI) received a USD 1.4 million grant from the Bill and Melinda Gates Foundation to ensure critical standards and reagents. These funds are available to the manufacturers that produce cholera vaccines at a lower price in the global health market.

Thus, the increasing incidences of cholera and rising initiatives and awareness regarding immunization are expected to drive the demand for cholera vaccines, thereby contributing to the growth of the market during the forecast period. However, a lack of access to adequate care for cholera, coupled with many unreported cases, is expected to pull back the growth of the market.

Whole-cell V. cholerae O1 with a recombinant B-subunit segment captures the largest market share. This cholera vaccine containing a combination of recombinant B-subunit and killed the whole cell V. cholerae O1 has been marketed for the last three decades. This vaccine is observed to provide 80-90% protection for six months, post-immunization, and in all cases of immunization of vaccines aged more than two years. In addition to this, these vaccines show around 50% of protection even after three years of immunization. The factors that are driving the growth of this segment are the high number of cholera cases recorded globally and the efficacy, and long-lasting post-immunization protections of the vaccine are expected to propel the segment’s growth over the forecast period.

An article published by ACS News Service in February 2022 reported that the Dukoral vaccine contains a mixture of formalin- and heal-killed V cholera O1 bacteria, representing both the Ogawa and Inaba serotypes and the classical and EI Tor biotypes and a recombinantly produced cholera toxin B subunit. The trials of this vaccine were undertaken in 90,000 children and women in Bangladesh and showed an 85% protective efficacy against cholera during the first 4-6 months and 50-60% efficacy over a 3-year follow-up period after two or three vaccination. Thus, the high efficacy of this vaccine is expected to increase the demand, thereby driving the growth of this segment.

Additionally, the high number of cholera cases recorded globally is also expected to increase the demand for cholera vaccines. For instance, European Center for Disease Prevention and Control (ECDC) in 2022 reported 25.8 thousand cholera cases in Pakistan, followed by 46.2 thousand cholera cases recorded in Bangladesh in the year 2022. Thus, a high number of cholera cases is expected to drive the growth of this segment.

Thus, the high number of cholera cases recorded globally and the efficacy and long-lasting post-immunization protections of the vaccine are expected to drive the growth of this segment.

North America consists of three countries, the United States, Canada, and Mexico. The region is expected to witness significant growth over the forecast period owing to the presence of advanced research and the major players that is leading to the development of a novel cholera vaccine, a high number of cholera cases recorded globally, and rising government initiatives.

The high number of cholera cases recorded in Mexico region is expected to increase the demand for cholera vaccines, thereby driving the growth of the market in the region. For instance, in October 2022, Mexico Health Ministry recorded 45,000 cholera cases in the country from January 2022 - September 2022. Thus, the high number of cholera cases is driving the growth of the studied market in the region.

Additionally, the rising government initiatives to control cholera are expected to drive the growth of the studied market in the region. For instance, in December 2021, Health Canada updated the guidelines on the prevention and control of infectious diseases like cholera. These initiatives are expected to increase awareness among the people in the country and thus increase the demand for cholera vaccines, thereby driving the growth of the studied market.

Furthermore, ongoing clinical studies are also driving the growth of the market. For instance, an article published by the journal Vaccine in May 2022 reported that a double-blind, randomized, placebo-controlled, phase I study conducted in the United States in which oral immunization with 6-g doses of MucoRice- cholera toxin (CTB) induced cross-reactive antigen-specific antibodies against CTB and heat-labile toxin B subunit (LTB) in serum and saliva in was conducted in healthy men and women. The study was successful, and this dose was safe and adequate to control cholera. Thus, such clinical studies for vaccine development in the country are expected to drive the growth of the studied market.

Thus, the high number of cholera cases recorded globally, rising government initiatives, and rising clinical studies are driving the growth of the studied market in the region.

The cholera Vaccine market is highly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known. Some of the significant companies in the market are Astellas Pharma Inc., Emergent BioSolutions Inc., GlaxoSmithKline plc (GSK), Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Sanofi, Takeda Pharmaceutical Co. Ltd, Valneva SE, PaxVax Inc., and Pfizer Inc.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support